About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5447169
Allelic
Composition
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (3 available); any Braf mutation (58 available)
Ptentm1Mro mutation (1 available); any Pten mutation (81 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• tamoxifen-treated mice must be euthanized between 40 and 70 days due to tumor load or ulceration
• in tamoxifen treated mice

neoplasm
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction
• however, no visceral metastasis is observed
• however, treatment with PLX4720 decreases tumor outgrowth
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression

integument
• in tamoxifen-treated mice
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction
• however, no visceral metastasis is observed
• however, treatment with PLX4720 decreases tumor outgrowth
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/16/2024
MGI 6.23
The Jackson Laboratory